Davenport Balanced Income holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
Davenport Balanced Income Fund DBALX
- NAV / 1-Day Return 13.25 / +0.15 %
- Total Assets 269.8M
-
Adj. Expense Ratio
0.930%
- Expense Ratio 0.920%
- Distribution Fee Level Above Average
- Share Class Type No Load
- Category Moderate Allocation
- Investment Style Large Value
- Credit Quality / Interest Rate Sensitivity —
- Status Open
- TTM Yield 2.66%
- Turnover 36%
USD | NAV as of Oct 02, 2026 | 1-Day Return as of Oct 02, 2026, 12:55 AM GMT+0
Morningstar’s Analysis DBALX
Will DBALX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 17.7
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Johnson & Johnson | 1.98 | 6M | Healthcare |
NextEra Energy Inc | 1.93 | 5M | Utilities |
Anheuser-Busch InBev SA/NV ADR | 1.81 | 5M | Consumer Defensive |
Federal Farm Credit Banks 4.94% | 1.73 | 5M | Government |
Berkshire Hathaway Inc Class B | 1.72 | 5M | Financial Services |
Federal Farm Credit Banks 5% | 1.72 | 5M | Government |
Meta Platforms Inc 4.95% | 1.71 | 5M | Corporate |
Federal Farm Credit Banks 5.03% | 1.71 | 5M | Government |
Federal Farm Credit Banks 5.33% | 1.69 | 5M | Government |
Abbott Laboratories 4.65% | 1.67 | 5M | Corporate |